Developing remyelinating and neuroprotective therapies for Multiple Sclerosis
Pheno Therapeutics aims to identify novel remyelinating agents and develop transformational therapeutics that enhance the repair of damaged myelin sheaths in Multiple Sclerosis patients.
The company was founded by Advent Life Sciences and the University of Edinburgh to build on the ground breaking research of Prof Siddharthan Chandran and Prof Neil Carragher, world class experts in multiple sclerosis and stem cell biology, and phenotypic screening, respectively.
CEO Fraser Murray
Advent Contact Dominic Schmidt I Fraser Murray
Advent founded Pheno Therapeutics in 2019.
Private Companies
Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802
Press Release. PRESS RELEASE 22 June 2026 Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802 US FDA clearance enables first-in-human study of PTD802, a…
Read More
Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802
Press Release. Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802 UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule…
Read More
Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease
Press Release. Preclinical program with potential for disease modifying therapeutic Edinburgh, UK January 11 2023 – Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of…
Read More
